Structure-activity studies on the CRF antagonist astressin identified the minimum peptide sequence needed for CRF receptor blockade, advancing toward smaller, more drug-like CRF antagonist anxiolytics.
Key findingSAR studies on astressin identified the minimal CRF antagonist sequence retaining biological activity at both CRF1 and CRF2 receptors, advancing desig
What the researchers found
SAR studies on astressin identified the minimal CRF antagonist sequence retaining biological activity at both CRF1 and CRF2 receptors, advancing design of smaller, more drug-like peptide antagonists for stress-related psychiatric disorders.
Why it matters
Relevant for neuropeptides, anxiety-mood, peptide-design.
How the study worked
in-vitro study on neuropeptides, anxiety-mood.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2004.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Structure-activity studies on the corticotropin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity.
Chembiochem : a European journal of chemical biology, 5(3), 340-8
Citation
Rijkers, Dirk T S; Kruijtzer, John A W; van Oostenbrugge, Marja; Ronken, Eric; den Hartog, Jack A J; Liskamp, Rob M J. (2004). Structure-activity studies on the corticotropin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity.. Chembiochem : a European journal of chemical biology, 5(3), 340-8.